Is NMRA or OTLK more undervalued in 2026?

CirclFi compares Neumora Therapeutics, Inc. (NMRA) and Outlook Therapeutics, Inc. (OTLK) using 13 institutional-grade valuation models. NMRA has a Quality of Company score of 3.8/10 while OTLK scores 3.7/10.

Which is a better buy — NMRA or OTLK?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NMRA and OTLK valuations compare?

NMRA at $1.85 and OTLK at $0.73 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NMRA vs OTLK Valuation Comparison 2026 — Intrinsic Value Analysis

NMRA

Biological Products, (No Diagnostic Substances)

Neumora Therapeutics, Inc.

Quality

3.8

out of 10

Value Trap

LOW

Price

$1.85

Last close

Models

7/13

Active

OTLK

Biological Products, (No Diagnostic Substances)

Outlook Therapeutics, Inc.

Quality

3.7

out of 10

Value Trap

LOW

Price

$0.73

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	NMRA Fair Value	NMRA Upside	OTLK Fair Value	OTLK Upside
Bayesian DCF	Intrinsic	$0.78	-57.9%	$0.07	-90.7%
Earnings Power Value	Intrinsic	—	—	$0.17	-35.9%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.55	-16.1%	$0.36	-50.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NMRA vs OTLK — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NMRA vs OTLK — Which Stock Is More Undervalued?

NMRA scores higher with a 3.8/10 quality rating vs OTLK's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Neumora Therapeutics, Inc. (NMRA) and Outlook Therapeutics, Inc. (OTLK) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NMRA currently trades at $1.85 with a QOC of 3.8/10, while OTLK trades at $0.73 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).